Biologics and Biosimilars Treatment Outlook Till 2022 | Revenue Models

1
The Future of the U.S. Biologics and Biosimilars
Treatment Market for Psoriasis
Published on 13 October, 2017 Number of
pages 104 Single User Price 4000
Biologics and Biosimilars Treatment
2
The psoriasis treatment market is dominated
by topical agents and photo therapy for the
non-severe forms (mainly corticosteroids), but
mild to severe forms are treated with systemic
agents. The psoriasis treatment market is
dominated by topical agents and photo therapy for
the non-severe forms (mainly corticosteroids),
but mild to severe forms are treated with
systemic agents.
3
Driven by improved efficacy, the first group
of anti TNF treatments led by Enbrel, Humira and
Remicade made strong penetration into the
psoriasis market. However the emergence of the
IL-17 inhibitor class driven by Novartis
Cosentyx and Eli Lillys Talz have set a new
benchmark for efficacy in moderate to severe
psoriasis treatment with potential for safety
improvement in comparison to the anti TNF drugs
given their greater specificity in immune
Suppression. MP Advisors expect the TNF class of
drugs to lose share to the newer brands with
improved clinical profiles in Psoriasis.
CLICK HERE TO CHECK COMPLETE REPORT
4
(No Transcript)
5
About Us MarketIntelReports (MIR) aim to
empower our clients to successfully manage and
outperform in their business decisions, we do
this by providing Premium Market Intelligence,
Strategic Insights and Databases from a range of
Global Publishers. MIR intends to be a one-stop
shop with an intuitive design, exhaustive
database, expert assistance, secure cart checkout
and data privacy integrated ensure that the
database is constantly updated to dynamically
meet the targeted, specific needs of our clients.
MarketIntelReports currently has more than 10,000
plus titles and 35 publishers on our platform
and growing consistently to fill the Biologics
and Biosimilars Treatment Market. MAKE A
ENQUIRY BEFORE BUYING
6
The Future of the U.S. Biologics and Biosimilars
Treatment Market for Psoriasis
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
The Future of the U.S. Biologics and Biosimilars
Treatment Market for Psoriasis and future
opportunities are provided in the report.
Contact 1-302-261-5343 pr_at_marketintelreports.c
om www.marketintelreports.com CLICK HERE TO
PROCURE THIS REPORT